Leqembi’s EU Approval Process Delayed Over Advisory Group COI Considerations

The decision is not related to the product.

 
• By Lisa Takagi
  
The court ruling led EMA to void the SAG-N decision for Leqembi due to potential COI concern.
The court ruling led EMA to void the SAG-N decision for Leqembi due to potential COI concerns • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography